...
首页> 外文期刊>The Japanese journal of antibiotics >Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria
【24h】

Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria

机译:生殖器对1996年至2001 - II之间的各种临床分离株的抗菌活性的年度变化。 革兰氏阴性细菌

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2001 were yearly evaluated and compared with those of other cephems, oxacephems and carbapenems. A total of 3,245 strains in 32 species of Gram-negative bacteria were isolated from the clinical materials annually collected from January to December, and consisted of Moraxella subgenus Branhamella catarrhalis, Escherichia coli, Citrobacter freundii, Citrobacter koseri, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Proteus mirabillis, Proteus vulgaris, Morganella morganii, Providencia spp. (P. alcalifaciens, P. rettgeri, P. stuartii), Pseudomonas aeruginosa, Pseudomonas putida, Burkholderia cepacia, Stenotrophomonas maltophilia, Haemophilus influenzae, Acinetobactor baumannii, Acinetobactor lwoffii, Bacteroides fragilis group (B. fragilis, B. vulgatus, B. distasonis, B. ovatus, B. thetaiotaomicron), and Prevotella spp. (P. melaninogenica, P. intermedia, P. bivia, P. oralis, P. denticola). CZOP possessed stable antibacterial activities against M. (B.) catarrhalis, E. coli, C. freundii, C. koseri, K. pneumoniae, K. oxytoca, E. aerogenes, E. cloacae, S. marcescens, P. mirabilis, P. vulgaris, M. morganii, Providencia spp., P. aeruginosa, and A. lwoffii throughout 6 years. The MIC90 of CZOP against those strains were consistent with those obtained from the studies performed until the new drug application approval. On the other hand, the MIC90 of CZOP against H. influenzae yearly obviously increased with approximately 64-time difference during the study period. The MIC90 of cefpirome, cefepime, and flomoxef against H. influenzae also yearly tended to rise. The present results demonstrated that CZOP had maintained the antibacterial activity against almost Gram-negative strains tested. However, the decrease in antibacterial activities of CZOP against B. cepacia, and H. influenzae was suggested.
机译:Cefozopran(Czop)的体外抗菌活性(Czop),Cephems的药物,在1996年至2001年之间获得的各种临床分离株每年进行评估,与其他Cephems,Oxacephems和Carbapems的临床分离物进行比较。从1月至12月的每年收集的临床材料中分离了32种革兰氏阴性细菌中共有3,245株,并由Moraxella subgageus Branhamella catarrhalis,大肠杆菌,柠檬酸杆菌,酸杆菌,Klebsiella肺炎,Klebsiella oxytoca,肠杆菌AEROGALES,EXEROBOCKS CLOACE,Serratia Marcescens,Proteus Mirabillis,ProteusVentgaris,Morganella Morganii,Providencia SPP。 (P.Alcalifaciens,P. Rettgeri,P. Stuartii),假单胞菌铜绿肽,假单胞菌普罗达,伯克德利亚猕猴桃,Stenotrophomonas麦芽毛虫,嗜血杆菌嗜血杆菌,Acinetobactor Baumannii,Acinetobactor Lwoffii,Bacteriles fragilis组(B.Frelilis,B.Virgilis,B. distasonis ,B. ovatus,B. thetaiotaomicron)和Fvootella spp。 (P. Melaninogenica,P.介质,P. Bivia,P. Oralis,P.Denticola)。 Czop具有针对M.(B.)Catarrhalis,大肠杆菌,C.Freundii,C.Koseri,K.Pneumoniae,K. oxytoca,E. Aercoges,E.Cloace,S.Marcescens,P.Mirabilis,P.Mirabilis,P.Mirabilis,P.Mirabilis,P.Mirabilis,S.Marciscens,P. Mirabilis,S. Marciscens,P. Mirabilis,P. Mirabilis,P. Mirabilis,P.Mirabilis,P.Mirabilis P.Vulgaris,M. Morganii,Providencia SPP。,P. Aeruginosa和A. Lwoffii整个6年。 Czop对那些菌株的MIC90与从进行的研究中获得的那些,直到新药申请批准。另一方面,Czop的MIC90对嗜血杆菌的嗜血杆菌在研究期间每年显然增加了大约64次差异。头孢哌粒,头孢噻肟和芬太福物的MIC90对抗H.Compenenzae也往上升起。目前的结果表明,Czop将抗菌活性保持对几乎测试的抗菌活性。然而,提出了对B.Cepacia的抗细菌活性的降低,并提出了流感的抗菌活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号